MedTrace Logo

nSTRIDE APS in Females With Primary Patellofemoral Osteoarthritis

NCT02610192 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2020-06-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate clinical outcomes following a single injection of nSTRIDE Autologous Protein Solution in females with isolated patellofemoral osteoarthritis. A secondary objective of this study is to document the duration of treatment effect following nSTRIDE injection.

Conditions

  • Patellofemoral Osteoarthritis

Interventions

DEVICE

nSTRIDE Autologous Protein Solution (APS) Kit

Intra-articular injection of APS

Sponsors & Collaborators

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Peter Verdonk, MD · AZ Monica, Deurne

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02610192 on ClinicalTrials.gov